TCGA-4E-A92E;UCEC;54;FEMALE;Stage I;Endometrioid endometrial adenocarcinoma;G1;2013;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-A5-A0G1;UCEC;67;FEMALE;Stage IA;Serous endometrial adenocarcinoma;G3;1996;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;TUMOR FREE;3251;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-A5-A0G5;UCEC;73;FEMALE;Stage IB;Serous endometrial adenocarcinoma;G3;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-A5-A0G9;UCEC;79;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2004;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-A5-A0GB;UCEC;65;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-A5-A0GD;UCEC;75;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G2;1999;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;TUMOR FREE;3423;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-A5-A0GE;UCEC;38;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G2;2002;Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-A5-A0GG;UCEC;76;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2003;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-A5-A0GH;UCEC;57;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2004;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-A5-A0GI;UCEC;63;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G2;2005;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-A5-A0GJ;UCEC;44;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G2;2005;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;12;Complete Remission/Response
TCGA-A5-A0GM;UCEC;53;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2006;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-A5-A0GN;UCEC;65;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G1;2006;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-A5-A0GP;UCEC;58;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2007;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-A5-A0GQ;UCEC;76;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G1;2007;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-A5-A0GR;UCEC;69;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G2;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-A5-A0GU;UCEC;58;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-A5-A0GV;UCEC;67;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;304;Complete Remission/Response
TCGA-A5-A0GW;UCEC;46;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-A5-A0GX;UCEC;53;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G2;2005;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-A5-A0R6;UCEC;64;FEMALE;Stage IIIC1;Serous endometrial adenocarcinoma;G3;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;New Primary Tumor;Other, specify;Rectum;961;Complete Remission/Response
TCGA-A5-A0R7;UCEC;55;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G2;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-A5-A0R8;UCEC;81;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G2;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;42;Complete Remission/Response
TCGA-A5-A0R9;UCEC;51;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G2;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-A5-A0RA;UCEC;68;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G2;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-A5-A0VO;UCEC;64;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G2;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;TUMOR FREE;875;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-A5-A0VP;UCEC;74;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-A5-A0VQ;UCEC;62;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-A5-A1OF;UCEC;47;FEMALE;Stage IA;Mixed serous and endometrioid;High Grade;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-A5-A1OH;UCEC;86;FEMALE;Stage IIIA;Serous endometrial adenocarcinoma;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-A5-A1OJ;UCEC;31;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G2;2010;Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-A5-A1OK;UCEC;63;FEMALE;Stage IIIA;Endometrioid endometrial adenocarcinoma;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-A5-A2K2;UCEC;77;FEMALE;Stage IA;Serous endometrial adenocarcinoma;G3;2003;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-A5-A2K3;UCEC;68;FEMALE;Stage IA;Serous endometrial adenocarcinoma;G3;2007;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-A5-A2K5;UCEC;76;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-A5-A2K7;UCEC;41;FEMALE;Stage II;Endometrioid endometrial adenocarcinoma;G3;2011;Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-A5-A3LO;UCEC;64;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-A5-A3LP;UCEC;74;FEMALE;Stage IB;Serous endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-A5-A7WJ;UCEC;64;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G2;2012;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-A5-AB3J;UCEC;52;FEMALE;Stage II;Endometrioid endometrial adenocarcinoma;G2;2013;Peri (6-12 months since last menstrual period);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AJ-A2QL;UCEC;60;FEMALE;Stage IIIC1;Endometrioid endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AJ-A2QM;UCEC;67;FEMALE;Stage II;Serous endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AJ-A2QN;UCEC;60;FEMALE;Stage II;Endometrioid endometrial adenocarcinoma;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AJ-A2QO;UCEC;85;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;TUMOR FREE;1045;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AJ-A3BD;UCEC;57;FEMALE;Stage IIIC2;Serous endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AJ-A3BF;UCEC;65;FEMALE;Stage IIIC2;Serous endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;Locoregional Recurrence;Other, specify;Retroperitoneal LNs;384;Complete Remission/Response
TCGA-AJ-A3BK;UCEC;68;FEMALE;Stage IC;Endometrioid endometrial adenocarcinoma;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AJ-A3EK;UCEC;53;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2011;Peri (6-12 months since last menstrual period);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AJ-A3EL;UCEC;47;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2010;Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AJ-A3EM;UCEC;69;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AJ-A3IA;UCEC;77;FEMALE;Stage IB;Serous endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AJ-A3NC;UCEC;63;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AJ-A3NE;UCEC;46;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2011;Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AJ-A3NF;UCEC;60;FEMALE;Stage IIIC;Serous endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AJ-A3NG;UCEC;83;FEMALE;Stage II;Mixed serous and endometrioid;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AJ-A3NH;UCEC;90;FEMALE;Stage IB;Serous endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;TUMOR FREE;310;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AJ-A3OJ;UCEC;54;FEMALE;Stage II;Endometrioid endometrial adenocarcinoma;G3;2011;Indeterminate (neither Pre or Postmenopausal);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AJ-A3OK;UCEC;73;FEMALE;Stage IA;Serous endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AJ-A3QS;UCEC;57;FEMALE;Stage IIIA;Serous endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AJ-A3TW;UCEC;78;FEMALE;Stage IB;Serous endometrial adenocarcinoma;G3;2012;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AJ-A4ZG;UCEC;53;FEMALE;Stage IVB;Serous endometrial adenocarcinoma;G3;2012;[Unknown];Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AJ-A5DV;UCEC;65;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2012;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AJ-A5DW;UCEC;56;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G2;2012;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AJ-A6NU;UCEC;64;FEMALE;Stage II;Endometrioid endometrial adenocarcinoma;G1;2012;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AJ-A8CT;UCEC;58;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2012;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AJ-A8CV;UCEC;58;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G2;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AP-A051;UCEC;69;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2003;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AP-A053;UCEC;90;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2004;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;TUMOR FREE;3365;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AP-A056;UCEC;64;FEMALE;Stage II;Endometrioid endometrial adenocarcinoma;G3;2004;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AP-A059;UCEC;69;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2006;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AP-A05A;UCEC;81;FEMALE;Stage II;Serous endometrial adenocarcinoma;G3;2006;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;TUMOR FREE;1944;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AP-A05D;UCEC;67;FEMALE;Stage IIIC2;Serous endometrial adenocarcinoma;G3;2007;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AP-A05H;UCEC;75;FEMALE;Stage IB;Serous endometrial adenocarcinoma;G3;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AP-A05J;UCEC;66;FEMALE;Stage II;Serous endometrial adenocarcinoma;G3;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AP-A05N;UCEC;58;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2009;Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);Dead;TUMOR FREE;726;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AP-A05O;UCEC;68;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;340;Complete Remission/Response
TCGA-AP-A05P;UCEC;54;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2009;Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AP-A0L9;UCEC;71;FEMALE;Stage IA;Serous endometrial adenocarcinoma;G3;2001;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AP-A0LD;UCEC;63;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2002;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AP-A0LE;UCEC;57;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2002;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AP-A0LG;UCEC;54;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2002;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AP-A0LI;UCEC;67;FEMALE;Stage IIIC2;Serous endometrial adenocarcinoma;G3;2003;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AP-A0LJ;UCEC;42;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2004;Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AP-A0LL;UCEC;56;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2004;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;790;Complete Remission/Response
TCGA-AP-A0LM;UCEC;33;FEMALE;Stage IIIC2;Endometrioid endometrial adenocarcinoma;G3;2004;Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AP-A0LN;UCEC;56;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2005;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AP-A0LP;UCEC;76;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2005;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AP-A0LQ;UCEC;59;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G2;2005;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AP-A0LS;UCEC;63;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G2;2006;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AP-A0LT;UCEC;57;FEMALE;Stage II;Endometrioid endometrial adenocarcinoma;G2;2006;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AP-A0LV;UCEC;39;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2009;Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AP-A1DH;UCEC;62;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2005;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AP-A1DK;UCEC;53;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2006;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AP-A1DM;UCEC;60;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2007;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AP-A1DO;UCEC;62;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G2;2007;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AP-A1DR;UCEC;59;FEMALE;Stage IIIC1;Endometrioid endometrial adenocarcinoma;G2;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AP-A1DV;UCEC;59;FEMALE;Stage II;Endometrioid endometrial adenocarcinoma;G3;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AP-A1E0;UCEC;40;FEMALE;Stage IIIC2;Endometrioid endometrial adenocarcinoma;G2;2009;Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AP-A1E1;UCEC;74;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G2;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AX-A05T;UCEC;82;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G1;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AX-A05U;UCEC;56;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G1;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AX-A05W;UCEC;60;FEMALE;Stage IIB;Endometrioid endometrial adenocarcinoma;G1;2004;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AX-A05Y;UCEC;57;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G1;2004;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;194;Complete Remission/Response
TCGA-AX-A05Z;UCEC;37;FEMALE;Stage IIIA;Endometrioid endometrial adenocarcinoma;G2;2006;Indeterminate (neither Pre or Postmenopausal);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AX-A060;UCEC;77;FEMALE;Stage IC;Endometrioid endometrial adenocarcinoma;G3;2007;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AX-A062;UCEC;53;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G1;2005;Indeterminate (neither Pre or Postmenopausal);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AX-A063;UCEC;63;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G2;2004;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AX-A064;UCEC;81;FEMALE;Stage IIA;Endometrioid endometrial adenocarcinoma;G2;2007;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AX-A06B;UCEC;72;FEMALE;Stage IIA;Endometrioid endometrial adenocarcinoma;G3;2005;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AX-A06F;UCEC;59;FEMALE;Stage IVA;Endometrioid endometrial adenocarcinoma;G3;2006;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AX-A06J;UCEC;71;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AX-A06L;UCEC;63;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G1;2006;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AX-A0IU;UCEC;79;FEMALE;Stage IIIC;Serous endometrial adenocarcinoma;G3;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AX-A0IW;UCEC;67;FEMALE;Stage IIIA;Serous endometrial adenocarcinoma;G3;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AX-A0IZ;UCEC;53;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2007;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AX-A0J0;UCEC;47;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G2;2006;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AX-A0J1;UCEC;80;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G2;2005;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AX-A2H2;UCEC;86;FEMALE;Stage IIA;Serous endometrial adenocarcinoma;G3;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;TUMOR FREE;145;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AX-A2H5;UCEC;67;FEMALE;Stage IIIC;Serous endometrial adenocarcinoma;G3;2005;[Not Available];Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AX-A2H8;UCEC;64;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2006;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AX-A2HA;UCEC;35;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2005;[Not Available];Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AX-A2HG;UCEC;56;FEMALE;Stage IC;Endometrioid endometrial adenocarcinoma;G3;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AX-A2HJ;UCEC;35;FEMALE;Stage IC;Endometrioid endometrial adenocarcinoma;G3;2009;[Not Available];Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-B5-A0JN;UCEC;84;FEMALE;Stage IVB;Serous endometrial adenocarcinoma;G3;2004;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-B5-A0JR;UCEC;73;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2006;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-B5-A0JS;UCEC;54;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2007;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-B5-A0JT;UCEC;63;FEMALE;Stage IIIA;Endometrioid endometrial adenocarcinoma;G1;2007;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-B5-A0JV;UCEC;63;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G2;2007;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;Locoregional Disease;Other, specify;vaginal wall;698;Complete Remission/Response
TCGA-B5-A0JX;UCEC;62;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2007;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-B5-A0JY;UCEC;50;FEMALE;Stage IIIC1;Endometrioid endometrial adenocarcinoma;G3;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-B5-A0K0;UCEC;48;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2008;Indeterminate (neither Pre or Postmenopausal);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-B5-A0K1;UCEC;69;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-B5-A0K2;UCEC;54;FEMALE;Stage IIIA;Endometrioid endometrial adenocarcinoma;G1;2008;Indeterminate (neither Pre or Postmenopausal);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-B5-A0K4;UCEC;51;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G2;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-B5-A0K6;UCEC;58;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-B5-A0K7;UCEC;64;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;Metastatic;Other, specify;vagina;322;Complete Remission/Response
TCGA-B5-A0K8;UCEC;71;FEMALE;Stage IB;Serous endometrial adenocarcinoma;G3;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-B5-A0K9;UCEC;88;FEMALE;Stage II;Endometrioid endometrial adenocarcinoma;G1;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;TUMOR FREE;409;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-B5-A11E;UCEC;53;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2010;Peri (6-12 months since last menstrual period);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-B5-A11F;UCEC;55;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G2;1995;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;Metastatic;Bone;#N/A;1610;Complete Remission/Response
TCGA-B5-A11G;UCEC;71;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2001;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-B5-A11H;UCEC;67;FEMALE;Stage IIIA;Endometrioid endometrial adenocarcinoma;G2;2004;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-B5-A11I;UCEC;65;FEMALE;Stage IVB;Endometrioid endometrial adenocarcinoma;G3;2005;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;Metastatic;Lung;#N/A;705;Complete Remission/Response
TCGA-B5-A11J;UCEC;64;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G2;2006;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-B5-A11L;UCEC;71;FEMALE;Stage IC;Endometrioid endometrial adenocarcinoma;G2;2007;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;TUMOR FREE;2240;Locoregional Recurrence;Other, specify;Vaginal Apex;131;Complete Remission/Response
TCGA-B5-A11M;UCEC;43;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2007;Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-B5-A11N;UCEC;69;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2007;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-B5-A11O;UCEC;62;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;New Primary Tumor;Other, specify;Right Breast;1924;Complete Remission/Response
TCGA-B5-A11Q;UCEC;64;FEMALE;Stage IIIA;Endometrioid endometrial adenocarcinoma;G1;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-B5-A11R;UCEC;51;FEMALE;Stage II;Endometrioid endometrial adenocarcinoma;G3;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-B5-A11S;UCEC;63;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G2;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;New Primary Tumor;Other, specify;Breast;41;Complete Remission/Response
TCGA-B5-A11U;UCEC;74;FEMALE;Stage IVB;Endometrioid endometrial adenocarcinoma;G3;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-B5-A11V;UCEC;64;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-B5-A11W;UCEC;61;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G2;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-B5-A11Y;UCEC;59;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G1;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-B5-A11Z;UCEC;61;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-B5-A121;UCEC;57;FEMALE;Stage IIIA;Endometrioid endometrial adenocarcinoma;G1;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-B5-A1MR;UCEC;65;FEMALE;Stage IIIA;Endometrioid endometrial adenocarcinoma;G3;1995;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-B5-A1MV;UCEC;84;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G2;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-B5-A1MW;UCEC;55;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;Locoregional Disease;Other, specify;vaginal cuff;311;Complete Remission/Response
TCGA-B5-A1MX;UCEC;47;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2010;Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-B5-A1MZ;UCEC;54;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2010;Indeterminate (neither Pre or Postmenopausal);Alive;TUMOR FREE;#N/A;Locoregional Recurrence;Other, specify;Vagina;613;Complete Remission/Response
TCGA-B5-A3FH;UCEC;74;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BG-A0LW;UCEC;47;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G2;2010;Indeterminate (neither Pre or Postmenopausal);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BG-A0LX;UCEC;57;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G2;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BG-A0M0;UCEC;66;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BG-A0M2;UCEC;62;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G2;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BG-A0M3;UCEC;74;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G2;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BG-A0M4;UCEC;60;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BG-A0M6;UCEC;73;FEMALE;Stage IIIC2;Serous endometrial adenocarcinoma;G3;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;TUMOR FREE;671;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BG-A0M7;UCEC;60;FEMALE;Stage IIIC1;Endometrioid endometrial adenocarcinoma;G2;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BG-A0M8;UCEC;50;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2008;Indeterminate (neither Pre or Postmenopausal);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BG-A0M9;UCEC;73;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G2;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BG-A0MC;UCEC;74;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BG-A0MG;UCEC;73;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2007;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BG-A0MH;UCEC;61;FEMALE;Stage IC;Endometrioid endometrial adenocarcinoma;G2;2007;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BG-A0MO;UCEC;63;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BG-A0MS;UCEC;53;FEMALE;Stage IIIC1;Endometrioid endometrial adenocarcinoma;G3;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BG-A0MU;UCEC;78;FEMALE;Stage IIIA;Endometrioid endometrial adenocarcinoma;G1;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BG-A0RY;UCEC;68;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G2;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BG-A0VT;UCEC;56;FEMALE;Stage IIIA;Endometrioid endometrial adenocarcinoma;G2;2010;Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BG-A0VV;UCEC;53;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2010;Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BG-A0VW;UCEC;77;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BG-A0VX;UCEC;58;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G1;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BG-A0VZ;UCEC;58;FEMALE;Stage IIIA;Endometrioid endometrial adenocarcinoma;G1;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BG-A0W1;UCEC;89;FEMALE;Stage II;Endometrioid endometrial adenocarcinoma;G2;2007;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BG-A0W2;UCEC;57;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2007;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BG-A0YU;UCEC;37;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2010;Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BG-A0YV;UCEC;67;FEMALE;Stage IIIA;Serous endometrial adenocarcinoma;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BG-A186;UCEC;61;FEMALE;Stage IIIA;Endometrioid endometrial adenocarcinoma;G2;2010;[Not Available];Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BG-A187;UCEC;65;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G2;2010;[Not Available];Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BG-A18A;UCEC;74;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BG-A18B;UCEC;53;FEMALE;Stage I;Endometrioid endometrial adenocarcinoma;G2;2010;Peri (6-12 months since last menstrual period);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BG-A18C;UCEC;72;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G2;2010;[Not Available];Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BG-A220;UCEC;69;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2010;[Not Available];Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BG-A221;UCEC;84;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BG-A222;UCEC;49;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2011;[Not Available];Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BG-A2AD;UCEC;63;FEMALE;Stage IIIB;Endometrioid endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BG-A2AE;UCEC;57;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2011;Peri (6-12 months since last menstrual period);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BG-A2L7;UCEC;68;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2011;[Not Available];Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BG-A3EW;UCEC;62;FEMALE;Stage III;Endometrioid endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BK-A0C9;UCEC;57;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G1;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BK-A0CA;UCEC;61;FEMALE;Stage IIIC;Mixed serous and endometrioid;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BK-A0CB;UCEC;60;FEMALE;Stage IIIC;Endometrioid endometrial adenocarcinoma;G2;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BK-A13C;UCEC;47;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G2;2010;Peri (6-12 months since last menstrual period);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BK-A26L;UCEC;71;FEMALE;Stage IIIC1;Serous endometrial adenocarcinoma;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BK-A4ZD;UCEC;42;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2012;Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BK-A56F;UCEC;75;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G1;2012;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BK-A6W3;UCEC;34;FEMALE;Stage II;Endometrioid endometrial adenocarcinoma;G2;2013;Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BK-A6W4;UCEC;62;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G2;2013;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BS-A0TC;UCEC;69;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G1;2004;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BS-A0TD;UCEC;65;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G1;2005;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BS-A0TI;UCEC;64;FEMALE;Stage IC;Endometrioid endometrial adenocarcinoma;G3;2006;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BS-A0TJ;UCEC;59;FEMALE;Stage IC;Endometrioid endometrial adenocarcinoma;G3;2006;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BS-A0U5;UCEC;76;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2003;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BS-A0U7;UCEC;63;FEMALE;Stage IC;Endometrioid endometrial adenocarcinoma;G2;2003;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;TUMOR FREE;935;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BS-A0U8;UCEC;55;FEMALE;Stage IIIC;Endometrioid endometrial adenocarcinoma;G1;2004;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BS-A0U9;UCEC;59;FEMALE;Stage IIA;Endometrioid endometrial adenocarcinoma;G3;2006;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BS-A0UA;UCEC;68;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G1;2004;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;Locoregional Disease;Other, specify;endometrium;520;Complete Remission/Response
TCGA-BS-A0UF;UCEC;65;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2004;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BS-A0UJ;UCEC;68;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2004;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BS-A0UL;UCEC;54;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2004;Peri (6-12 months since last menstrual period);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BS-A0UT;UCEC;62;FEMALE;Stage IIB;Endometrioid endometrial adenocarcinoma;G2;2005;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BS-A0UV;UCEC;55;FEMALE;Stage IIIC;Endometrioid endometrial adenocarcinoma;G3;2005;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BS-A0V4;UCEC;56;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G1;2006;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BS-A0V6;UCEC;55;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G1;2006;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BS-A0V7;UCEC;48;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G1;2006;Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BS-A0V8;UCEC;68;FEMALE;Stage IIB;Endometrioid endometrial adenocarcinoma;G2;2006;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BS-A0VI;UCEC;58;FEMALE;Stage IIB;Endometrioid endometrial adenocarcinoma;G3;2006;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BS-A0WQ;UCEC;55;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G2;2006;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A0ZN;UCEC;60;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2009;Peri (6-12 months since last menstrual period);Alive;TUMOR FREE;#N/A;New Primary Tumor;Other, specify;Breast left;448;Complete Remission/Response
TCGA-D1-A0ZO;UCEC;75;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G1;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A0ZP;UCEC;59;FEMALE;Stage IVA;Serous endometrial adenocarcinoma;G3;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;Locoregional Disease;Other, specify;Recurrent endometrial carcinoma in retriponeal lymphnodes;629;Complete Remission/Response
TCGA-D1-A0ZQ;UCEC;90;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G2;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A0ZR;UCEC;57;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G2;2009;Indeterminate (neither Pre or Postmenopausal);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A0ZS;UCEC;54;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A0ZU;UCEC;34;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G2;2009;Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A0ZV;UCEC;58;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G2;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A0ZZ;UCEC;80;FEMALE;Stage IB;Mixed serous and endometrioid;G3;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A101;UCEC;60;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G2;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A102;UCEC;49;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G2;2009;Peri (6-12 months since last menstrual period);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A103;UCEC;87;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G1;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A15V;UCEC;68;FEMALE;Stage IB;Serous endometrial adenocarcinoma;G3;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A15W;UCEC;58;FEMALE;Stage IIIC;Endometrioid endometrial adenocarcinoma;G1;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A15X;UCEC;45;FEMALE;Stage IA;Serous endometrial adenocarcinoma;High Grade;2008;Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A15Z;UCEC;72;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G2;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;TUMOR FREE;58;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A160;UCEC;70;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G2;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A161;UCEC;78;FEMALE;Stage IC;Endometrioid endometrial adenocarcinoma;G1;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A162;UCEC;69;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G1;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A163;UCEC;50;FEMALE;Stage IIIC;Endometrioid endometrial adenocarcinoma;G2;2008;Peri (6-12 months since last menstrual period);Alive;TUMOR FREE;#N/A;Metastatic;Other, specify;Paraaortic retroperitoneal lymphnode;223;Complete Remission/Response
TCGA-D1-A165;UCEC;64;FEMALE;Stage IIIA;Endometrioid endometrial adenocarcinoma;G1;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A167;UCEC;70;FEMALE;Stage IC;Endometrioid endometrial adenocarcinoma;G2;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A168;UCEC;67;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A16B;UCEC;64;FEMALE;Stage IC;Endometrioid endometrial adenocarcinoma;G2;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A16D;UCEC;49;FEMALE;Stage IC;Endometrioid endometrial adenocarcinoma;G2;2008;Peri (6-12 months since last menstrual period);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A16E;UCEC;73;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G1;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A16F;UCEC;60;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G2;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A16I;UCEC;62;FEMALE;Stage IC;Serous endometrial adenocarcinoma;High Grade;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;TUMOR FREE;350;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A16J;UCEC;61;FEMALE;Stage IIB;Endometrioid endometrial adenocarcinoma;G2;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A16N;UCEC;51;FEMALE;Stage IIIA;Endometrioid endometrial adenocarcinoma;G3;2009;Peri (6-12 months since last menstrual period);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A16O;UCEC;44;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G1;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A16Q;UCEC;54;FEMALE;Stage II;Endometrioid endometrial adenocarcinoma;G2;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A16R;UCEC;39;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2010;Indeterminate (neither Pre or Postmenopausal);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A16S;UCEC;70;FEMALE;Stage IIIC;Serous endometrial adenocarcinoma;High Grade;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A16V;UCEC;78;FEMALE;Stage IIIC;Endometrioid endometrial adenocarcinoma;G3;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;TUMOR FREE;120;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A16X;UCEC;54;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G2;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A16Y;UCEC;56;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G1;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A174;UCEC;51;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2010;Indeterminate (neither Pre or Postmenopausal);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A175;UCEC;48;FEMALE;Stage IC;Endometrioid endometrial adenocarcinoma;G3;2009;Indeterminate (neither Pre or Postmenopausal);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A176;UCEC;67;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G2;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A177;UCEC;70;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G2;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;Locoregional Disease;Other, specify;paraaortic lymph nodes;347;Complete Remission/Response
TCGA-D1-A17A;UCEC;59;FEMALE;Stage IIA;Endometrioid endometrial adenocarcinoma;G3;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A17B;UCEC;69;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G2;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A17C;UCEC;78;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A17D;UCEC;58;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A17F;UCEC;68;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G2;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A17H;UCEC;61;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G1;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A17K;UCEC;74;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G2;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;Locoregional Disease;Other, specify;Vagina, apex;815;Complete Remission/Response
TCGA-D1-A17L;UCEC;81;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A17M;UCEC;56;FEMALE;Stage II;Endometrioid endometrial adenocarcinoma;G1;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A17N;UCEC;46;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G2;2009;Peri (6-12 months since last menstrual period);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A17Q;UCEC;54;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G2;2009;Peri (6-12 months since last menstrual period);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A17R;UCEC;58;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G2;2009;Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);Dead;TUMOR FREE;339;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A17S;UCEC;59;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A17T;UCEC;67;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G2;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A17U;UCEC;53;FEMALE;Stage IIIC2;Endometrioid endometrial adenocarcinoma;G2;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A1NS;UCEC;53;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A1NU;UCEC;74;FEMALE;Stage IA;Serous endometrial adenocarcinoma;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A1NW;UCEC;72;FEMALE;Stage IVB;Mixed serous and endometrioid;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A1NY;UCEC;67;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A1NZ;UCEC;60;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A1O0;UCEC;77;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A1O5;UCEC;61;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A1O7;UCEC;60;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A1O8;UCEC;70;FEMALE;Stage IIIC;Endometrioid endometrial adenocarcinoma;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;TUMOR FREE;120;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A2G7;UCEC;65;FEMALE;Stage IB;Serous endometrial adenocarcinoma;G3;2007;Peri (6-12 months since last menstrual period);Dead;TUMOR FREE;1793;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A3DA;UCEC;77;FEMALE;Stage IIIC1;Endometrioid endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A3DH;UCEC;71;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-D1-A3JQ;UCEC;61;FEMALE;Stage IIIC;Serous endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-DI-A0WH;UCEC;64;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2010;[Not Available];Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-DI-A1BU;UCEC;55;FEMALE;Stage IIB;Mixed serous and endometrioid;G3;2008;[Not Available];Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-DI-A1BY;UCEC;63;FEMALE;Stage IIB;Endometrioid endometrial adenocarcinoma;G2;2008;[Not Available];Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-DI-A1C3;UCEC;38;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G2;2008;[Not Available];Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-DI-A2QY;UCEC;64;FEMALE;Stage IIB;Serous endometrial adenocarcinoma;G3;2003;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;TUMOR FREE;3349;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-E6-A1LX;UCEC;40;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2006;Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-E6-A1LZ;UCEC;76;FEMALE;Stage IA;Serous endometrial adenocarcinoma;G3;2007;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-E6-A1M0;UCEC;56;FEMALE;Stage IIIC;Endometrioid endometrial adenocarcinoma;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-E6-A2P9;UCEC;65;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-E6-A8L9;UCEC;61;FEMALE;Stage IB;Serous endometrial adenocarcinoma;G3;2012;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EC-A1NJ;UCEC;73;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G2;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EC-A24G;UCEC;57;FEMALE;Stage II;Endometrioid endometrial adenocarcinoma;G3;2011;Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EO-A1Y5;UCEC;63;FEMALE;Stage IIIC2;Serous endometrial adenocarcinoma;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EO-A1Y8;UCEC;87;FEMALE;Stage IA;Serous endometrial adenocarcinoma;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EO-A22R;UCEC;56;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EO-A22S;UCEC;58;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EO-A22T;UCEC;56;FEMALE;Stage II;Endometrioid endometrial adenocarcinoma;G3;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EO-A22U;UCEC;83;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EO-A22X;UCEC;36;FEMALE;Stage IIIA;Endometrioid endometrial adenocarcinoma;G3;2008;Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EO-A22Y;UCEC;68;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EO-A2CG;UCEC;69;FEMALE;Stage IA;Serous endometrial adenocarcinoma;G3;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EO-A3AS;UCEC;86;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EO-A3AU;UCEC;72;FEMALE;Stage II;Endometrioid endometrial adenocarcinoma;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;New Primary Tumor;Lung;#N/A;1178;Complete Remission/Response
TCGA-EO-A3AV;UCEC;51;FEMALE;Stage IIIC1;Endometrioid endometrial adenocarcinoma;G3;2010;Peri (6-12 months since last menstrual period);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EO-A3AZ;UCEC;80;FEMALE;Stage IB;Mixed serous and endometrioid;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EO-A3B1;UCEC;63;FEMALE;Stage IB;Serous endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EO-A3KU;UCEC;68;FEMALE;Stage II;Serous endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EO-A3KW;UCEC;72;FEMALE;Stage IA;Serous endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EO-A3KX;UCEC;80;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EO-A3L0;UCEC;76;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EY-A1G8;UCEC;83;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;TUMOR FREE;456;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EY-A1GC;UCEC;62;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EY-A1GD;UCEC;51;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2009;Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EY-A1GE;UCEC;67;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EY-A1GF;UCEC;75;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G2;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EY-A1GH;UCEC;70;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G2;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EY-A1GI;UCEC;52;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G2;2009;Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EY-A1GJ;UCEC;73;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EY-A1GK;UCEC;74;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EY-A1GL;UCEC;51;FEMALE;Stage II;Endometrioid endometrial adenocarcinoma;G2;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EY-A1GP;UCEC;54;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EY-A1GR;UCEC;67;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EY-A1GT;UCEC;68;FEMALE;Stage IIIA;Endometrioid endometrial adenocarcinoma;G1;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EY-A1GU;UCEC;66;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G2;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;TUMOR FREE;997;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EY-A1GV;UCEC;75;FEMALE;Stage IIIC1;Mixed serous and endometrioid;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EY-A1GX;UCEC;76;FEMALE;Stage IIIA;Endometrioid endometrial adenocarcinoma;G2;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;TUMOR FREE;1127;Locoregional Recurrence;Other, specify;pelvic mass;743;Complete Remission/Response
TCGA-EY-A210;UCEC;82;FEMALE;Stage IIIC2;Mixed serous and endometrioid;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EY-A214;UCEC;66;FEMALE;Stage IIIC1;Endometrioid endometrial adenocarcinoma;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EY-A215;UCEC;60;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EY-A2OM;UCEC;55;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EY-A2OO;UCEC;56;FEMALE;Stage IB;Mixed serous and endometrioid;G3;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EY-A2OP;UCEC;63;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EY-A2OQ;UCEC;61;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EY-A3L3;UCEC;82;FEMALE;Stage IA;Serous endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EY-A547;UCEC;75;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EY-A548;UCEC;83;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2012;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EY-A549;UCEC;78;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2012;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EY-A54A;UCEC;67;FEMALE;Stage IIIC2;Endometrioid endometrial adenocarcinoma;G3;2012;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EY-A5W2;UCEC;72;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2012;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EY-A72D;UCEC;87;FEMALE;Stage II;Endometrioid endometrial adenocarcinoma;G3;2013;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-FI-A2CX;UCEC;82;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-FI-A2CY;UCEC;60;FEMALE;Stage IA;Mixed serous and endometrioid;G3;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-FI-A2D0;UCEC;55;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2008;Peri (6-12 months since last menstrual period);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-FI-A2D6;UCEC;74;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;TUMOR FREE;767;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-FI-A2EU;UCEC;68;FEMALE;Stage IA;Serous endometrial adenocarcinoma;G3;2003;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-FI-A2EY;UCEC;63;FEMALE;Stage IIIA;Serous endometrial adenocarcinoma;G3;2006;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;TUMOR FREE;880;New Primary Tumor;Lung;#N/A;577;Complete Remission/Response
TCGA-FI-A2F4;UCEC;64;FEMALE;Stage IC;Endometrioid endometrial adenocarcinoma;G3;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-FI-A2F9;UCEC;79;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-FI-A3PX;UCEC;57;FEMALE;Stage IIIC2;Serous endometrial adenocarcinoma;High Grade;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-KP-A3W0;UCEC;72;FEMALE;Stage IB;Serous endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-KP-A3W1;UCEC;76;FEMALE;Stage IA;Serous endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-PG-A5BC;UCEC;72;FEMALE;Stage II;Serous endometrial adenocarcinoma;G3;2012;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-PG-A6IB;UCEC;68;FEMALE;Stage IA;Serous endometrial adenocarcinoma;G3;2012;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-PG-A914;UCEC;73;FEMALE;Stage IA;Serous endometrial adenocarcinoma;G3;2013;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-PG-A915;UCEC;60;FEMALE;Stage IA;Serous endometrial adenocarcinoma;G3;2013;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-PG-A916;UCEC;70;FEMALE;Stage I;Endometrioid endometrial adenocarcinoma;G2;2013;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-PG-A917;UCEC;74;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G2;2012;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-QF-A5YS;UCEC;57;FEMALE;Stage II;Mixed serous and endometrioid;G2;2012;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-QF-A5YT;UCEC;57;FEMALE;Stage II;Endometrioid endometrial adenocarcinoma;G1;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-QS-A5YQ;UCEC;55;FEMALE;Stage IIIA;Endometrioid endometrial adenocarcinoma;G1;2013;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-SJ-A6ZI;UCEC;64;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G1;2013;[Unknown];Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-SJ-A6ZJ;UCEC;61;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G2;2012;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-SL-A6JA;UCEC;77;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2013;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BG-A0MT;UCEC;64;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G2;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;Locoregional Disease;Other, specify;locally in the endometrium;565;Partial Remission/Response
TCGA-D1-A3JP;UCEC;61;FEMALE;Stage IA;Serous endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Partial Remission/Response
TCGA-2E-A9G8;UCEC;59;FEMALE;Stage III;Endometrioid endometrial adenocarcinoma;G2;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;Locoregional Recurrence;Other, specify;abdominal wall;335;Progressive Disease
TCGA-B5-A0JZ;UCEC;60;FEMALE;Stage IIIC1;Endometrioid endometrial adenocarcinoma;G3;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;Metastatic;Other, specify;inguinal lymph node;356;Progressive Disease
TCGA-EC-A1QX;UCEC;71;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;219;Progressive Disease
TCGA-PG-A7D5;UCEC;62;FEMALE;Stage IA;Serous endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;TUMOR FREE;#N/A;#N/A;#N/A;#N/A;#N/A;Stable Disease
TCGA-A5-A0G2;UCEC;57;FEMALE;Stage IIIB;Serous endometrial adenocarcinoma;G3;1997;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;WITH TUMOR;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-A5-A0G3;UCEC;61;FEMALE;Stage IIIC2;Serous endometrial adenocarcinoma;G3;2007;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;WITH TUMOR;#N/A;#N/A;#N/A;#N/A;795;Complete Remission/Response
TCGA-A5-A1OG;UCEC;65;FEMALE;Stage IIIC2;Serous endometrial adenocarcinoma;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;973;Metastatic;Lung;#N/A;337;Complete Remission/Response
TCGA-A5-A2K4;UCEC;69;FEMALE;Stage IIIA;Serous endometrial adenocarcinoma;G3;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;871;Metastatic;Other, specify;Bowel;528;Complete Remission/Response
TCGA-A5-A7WK;UCEC;71;FEMALE;Stage IA;Mixed serous and endometrioid;G3;2013;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;WITH TUMOR;#N/A;Locoregional Recurrence;Other, specify;Paraaortic lymph node;350;Complete Remission/Response
TCGA-AJ-A2QK;UCEC;65;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;WITH TUMOR;#N/A;Distant Metastasis;Liver;#N/A;606;Complete Remission/Response
TCGA-AJ-A3BG;UCEC;65;FEMALE;Stage IA;Mixed serous and endometrioid;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;WITH TUMOR;#N/A;Locoregional Recurrence;Other, specify;Vagina;480;Complete Remission/Response
TCGA-AJ-A3I9;UCEC;52;FEMALE;Stage II;Endometrioid endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;519;Distant Metastasis;Bone;#N/A;370;Complete Remission/Response
TCGA-AJ-A3OL;UCEC;55;FEMALE;Stage IIIA;Endometrioid endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;449;Distant Metastasis;Other, specify;Lung, Liver, and Brain;424;Complete Remission/Response
TCGA-AP-A052;UCEC;59;FEMALE;Stage IVB;Serous endometrial adenocarcinoma;G3;2004;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;669;#N/A;#N/A;#N/A;394;Complete Remission/Response
TCGA-AP-A054;UCEC;64;FEMALE;Stage IIIC1;Endometrioid endometrial adenocarcinoma;G3;2004;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;709;#N/A;#N/A;#N/A;566;Complete Remission/Response
TCGA-AP-A0L8;UCEC;70;FEMALE;Stage IIIC2;Serous endometrial adenocarcinoma;G3;2000;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;1484;#N/A;#N/A;#N/A;1453;Complete Remission/Response
TCGA-AP-A0LH;UCEC;60;FEMALE;Stage IA;Mixed serous and endometrioid;G3;2002;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;1106;#N/A;#N/A;#N/A;302;Complete Remission/Response
TCGA-AP-A0LO;UCEC;45;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G2;2005;Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);Dead;WITH TUMOR;1016;#N/A;#N/A;#N/A;516;Complete Remission/Response
TCGA-AP-A1DP;UCEC;70;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G2;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;1081;Metastatic;Other, specify;Lung, liver, lymph nodes;831;Complete Remission/Response
TCGA-AP-A1DQ;UCEC;76;FEMALE;Stage IIIC1;Serous endometrial adenocarcinoma;High Grade;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;1423;Metastatic;Other, specify;Lymph nodes, lung, bone;905;Complete Remission/Response
TCGA-AP-A5FX;UCEC;68;FEMALE;Stage IIIC1;Mixed serous and endometrioid;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;1099;Locoregional Recurrence;Other, specify;"Retroperitoneal LN; vulvar mass";407;Complete Remission/Response
TCGA-AX-A06H;UCEC;60;FEMALE;Stage IIIA;Endometrioid endometrial adenocarcinoma;G1;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;WITH TUMOR;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AX-A0IS;UCEC;52;FEMALE;Stage IC;Endometrioid endometrial adenocarcinoma;G2;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;1858;#N/A;#N/A;#N/A;448;Complete Remission/Response
TCGA-AX-A1C5;UCEC;47;FEMALE;Stage IIIC;Endometrioid endometrial adenocarcinoma;G3;2009;Indeterminate (neither Pre or Postmenopausal);Alive;WITH TUMOR;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AX-A2H4;UCEC;66;FEMALE;Stage IIIA;Serous endometrial adenocarcinoma;G3;2006;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;916;Locoregional Disease;Other, specify;Vaginal cuff, iliac;520;Complete Remission/Response
TCGA-AX-A2H7;UCEC;87;FEMALE;Stage IC;Endometrioid endometrial adenocarcinoma;G3;2008;[Not Available];Dead;WITH TUMOR;1241;Metastatic;Lung;#N/A;684;Complete Remission/Response
TCGA-AX-A2HC;UCEC;53;FEMALE;Stage IIIC;Endometrioid endometrial adenocarcinoma;G3;2006;[Not Available];Alive;WITH TUMOR;#N/A;Metastatic;Other, specify;Abdomen;756;Complete Remission/Response
TCGA-AX-A2HF;UCEC;67;FEMALE;Stage IB;Serous endometrial adenocarcinoma;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;WITH TUMOR;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-AX-A2HK;UCEC;77;FEMALE;Stage IIIC;Endometrioid endometrial adenocarcinoma;G3;2005;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;90;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-B5-A0KB;UCEC;62;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;WITH TUMOR;#N/A;Locoregional Disease;Other, specify;cul de sac mass;689;Complete Remission/Response
TCGA-B5-A1MU;UCEC;79;FEMALE;Stage IVB;Serous endometrial adenocarcinoma;G3;2006;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;1548;New Primary Tumor;Other, specify;Breast;1365;Complete Remission/Response
TCGA-B5-A1N2;UCEC;70;FEMALE;Stage IIIC1;Serous endometrial adenocarcinoma;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;954;Distant Metastasis;Brain;#N/A;804;Complete Remission/Response
TCGA-B5-A3S1;UCEC;71;FEMALE;Stage IIIC1;Serous endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;WITH TUMOR;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BK-A0CC;UCEC;69;FEMALE;Stage IIIC;Serous endometrial adenocarcinoma;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;WITH TUMOR;#N/A;Locoregional Recurrence;Other, specify;Right Pelvic Mass;1010;Complete Remission/Response
TCGA-BK-A13B;UCEC;58;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;WITH TUMOR;#N/A;Locoregional Recurrence;Other, specify;Vaginal;760;Complete Remission/Response
TCGA-BS-A0T9;UCEC;39;FEMALE;Stage IVB;Endometrioid endometrial adenocarcinoma;G3;2005;Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);Dead;WITH TUMOR;1428;#N/A;#N/A;#N/A;634;Complete Remission/Response
TCGA-BS-A0TG;UCEC;60;FEMALE;Stage IIIA;Endometrioid endometrial adenocarcinoma;G2;2005;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;WITH TUMOR;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-BS-A0UM;UCEC;64;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G1;2005;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;WITH TUMOR;#N/A;Metastatic;Brain;#N/A;1454;Complete Remission/Response
TCGA-D1-A169;UCEC;63;FEMALE;Stage IV;Endometrioid endometrial adenocarcinoma;G2;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;WITH TUMOR;#N/A;Metastatic;Other, specify;Bladder nodule;519;Complete Remission/Response
TCGA-D1-A16G;UCEC;74;FEMALE;Stage IV;Serous endometrial adenocarcinoma;High Grade;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;834;Locoregional Disease;Other, specify;Lymph nodes;642;Complete Remission/Response
TCGA-D1-A179;UCEC;76;FEMALE;Stage IIIC;Serous endometrial adenocarcinoma;High Grade;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;448;Metastatic;Lung;#N/A;427;Complete Remission/Response
TCGA-D1-A1NX;UCEC;66;FEMALE;Stage IIIC;Serous endometrial adenocarcinoma;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;WITH TUMOR;#N/A;Metastatic;Other, specify;Supraclavicular lymphnodes;476;Complete Remission/Response
TCGA-D1-A2G5;UCEC;50;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2007;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;WITH TUMOR;#N/A;Distant Metastasis;Other, specify;omentum;1122;Complete Remission/Response
TCGA-DI-A1NN;UCEC;63;FEMALE;Stage IIIC;Serous endometrial adenocarcinoma;G3;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;WITH TUMOR;#N/A;Metastatic;Other, specify;vagina;1023;Complete Remission/Response
TCGA-DI-A1NO;UCEC;68;FEMALE;Stage IIIA;Endometrioid endometrial adenocarcinoma;G3;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;285;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-EO-A3AY;UCEC;58;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;WITH TUMOR;#N/A;Locoregional Recurrence;Other, specify;Vaginal Vault;1163;Complete Remission/Response
TCGA-EY-A1G7;UCEC;86;FEMALE;Stage II;Endometrioid endometrial adenocarcinoma;G2;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;189;#N/A;#N/A;#N/A;95;Complete Remission/Response
TCGA-EY-A1GM;UCEC;60;FEMALE;Stage IIIA;Mixed serous and endometrioid;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;995;Locoregional Recurrence;#N/A;#N/A;791;Complete Remission/Response
TCGA-EY-A1GO;UCEC;65;FEMALE;Stage IIIC1;Endometrioid endometrial adenocarcinoma;G2;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;WITH TUMOR;#N/A;Metastatic;Lung;#N/A;517;Complete Remission/Response
TCGA-EY-A1GQ;UCEC;76;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;WITH TUMOR;#N/A;Metastatic;Other, specify;R external iliac node, presacral peritoneal implant, ascitic fluid;334;Complete Remission/Response
TCGA-EY-A3QX;UCEC;64;FEMALE;Stage IVB;Serous endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;989;Locoregional Recurrence;Other, specify;Peritoneum;896;Complete Remission/Response
TCGA-FI-A2D2;UCEC;66;FEMALE;Stage IB;Mixed serous and endometrioid;G3;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;2352;Locoregional Recurrence;Lung;Liver;1917;Complete Remission/Response
TCGA-FI-A2EW;UCEC;71;FEMALE;Stage IIB;Serous endometrial adenocarcinoma;G3;2005;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;WITH TUMOR;#N/A;Metastatic;Liver;#N/A;1169;Complete Remission/Response
TCGA-FI-A2EX;UCEC;58;FEMALE;Stage IIIA;Serous endometrial adenocarcinoma;G3;2005;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;WITH TUMOR;#N/A;Metastatic;#N/A;#N/A;213;Complete Remission/Response
TCGA-FI-A2F8;UCEC;64;FEMALE;Stage II;Serous endometrial adenocarcinoma;G3;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;WITH TUMOR;#N/A;#N/A;#N/A;#N/A;#N/A;Complete Remission/Response
TCGA-JU-AAVI;UCEC;61;FEMALE;Stage IIIC1;Serous endometrial adenocarcinoma;G3;2013;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;540;Distant Metastasis;Other, specify;Porta Hepatis;505;Complete Remission/Response
TCGA-KP-A3W3;UCEC;72;FEMALE;Stage IB;Serous endometrial adenocarcinoma;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;WITH TUMOR;#N/A;Distant Metastasis;Liver;#N/A;661;Complete Remission/Response
TCGA-A5-A0GA;UCEC;67;FEMALE;Stage IIIC2;Endometrioid endometrial adenocarcinoma;G3;2006;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;543;#N/A;#N/A;#N/A;#N/A;Partial Remission/Response
TCGA-AP-A1E3;UCEC;45;FEMALE;Stage IIIC1;Endometrioid endometrial adenocarcinoma;G3;2009;Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);Alive;WITH TUMOR;#N/A;#N/A;#N/A;#N/A;#N/A;Partial Remission/Response
TCGA-AX-A2HD;UCEC;69;FEMALE;Stage IIIA;Endometrioid endometrial adenocarcinoma;G3;2008;[Not Available];Alive;WITH TUMOR;#N/A;#N/A;#N/A;#N/A;#N/A;Partial Remission/Response
TCGA-AX-A2HH;UCEC;60;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G3;2010;[Not Available];Alive;WITH TUMOR;#N/A;#N/A;#N/A;#N/A;#N/A;Partial Remission/Response
TCGA-B5-A1MS;UCEC;60;FEMALE;Stage IC;Serous endometrial adenocarcinoma;G3;2003;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;3112;Locoregional Recurrence;Other, specify;Supraclavicular Fossa;2706;Partial Remission/Response
TCGA-EY-A1H0;UCEC;57;FEMALE;Stage IIIC2;Endometrioid endometrial adenocarcinoma;G2;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;WITH TUMOR;#N/A;#N/A;#N/A;#N/A;#N/A;Partial Remission/Response
TCGA-EY-A212;UCEC;83;FEMALE;Stage IIIC1;Serous endometrial adenocarcinoma;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;310;#N/A;#N/A;#N/A;#N/A;Partial Remission/Response
TCGA-FI-A2D4;UCEC;44;FEMALE;Stage IIIC;Endometrioid endometrial adenocarcinoma;G3;2009;Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);Dead;WITH TUMOR;243;#N/A;#N/A;#N/A;#N/A;Partial Remission/Response
TCGA-FI-A2D5;UCEC;56;FEMALE;Stage IVB;Endometrioid endometrial adenocarcinoma;G3;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;421;Metastatic;Other, specify;vaginal cuff;280;Partial Remission/Response
TCGA-KP-A3W4;UCEC;63;FEMALE;Stage IIIA;Serous endometrial adenocarcinoma;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;554;Distant Metastasis;Liver;#N/A;321;Partial Remission/Response
TCGA-AJ-A23N;UCEC;70;FEMALE;Stage IIIA;Serous endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;439;#N/A;#N/A;#N/A;#N/A;Progressive Disease
TCGA-AP-A1E4;UCEC;54;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G2;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;WITH TUMOR;#N/A;Metastatic;Other, specify;Bone, lymph nodes;158;Progressive Disease
TCGA-AP-A3K1;UCEC;56;FEMALE;Stage IVB;Serous endometrial adenocarcinoma;High Grade;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;666;Locoregional Recurrence;Other, specify;Paracolic gutter;198;Progressive Disease
TCGA-AX-A05S;UCEC;81;FEMALE;Stage IIIC;Endometrioid endometrial adenocarcinoma;G3;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;413;#N/A;#N/A;#N/A;338;Progressive Disease
TCGA-AX-A06D;UCEC;82;FEMALE;Stage IIIA;Endometrioid endometrial adenocarcinoma;G2;2007;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;373;#N/A;#N/A;#N/A;253;Progressive Disease
TCGA-AX-A1CF;UCEC;69;FEMALE;Stage IVB;Endometrioid endometrial adenocarcinoma;G3;2004;[Not Available];Alive;WITH TUMOR;#N/A;#N/A;#N/A;#N/A;875;Progressive Disease
TCGA-BG-A0MA;UCEC;60;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;326;Metastatic;Bone;#N/A;70;Progressive Disease
TCGA-BG-A0MK;UCEC;52;FEMALE;Stage IIB;Endometrioid endometrial adenocarcinoma;G3;2006;Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);Dead;WITH TUMOR;1317;#N/A;#N/A;#N/A;#N/A;Progressive Disease
TCGA-BG-A3PP;UCEC;82;FEMALE;Stage II;Serous endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;WITH TUMOR;#N/A;Locoregional Recurrence;Other, specify;Vagina apex;665;Progressive Disease
TCGA-BS-A0TE;UCEC;35;FEMALE;Stage IVB;Endometrioid endometrial adenocarcinoma;G3;2005;Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);Dead;WITH TUMOR;146;#N/A;#N/A;#N/A;58;Progressive Disease
TCGA-E6-A2P8;UCEC;53;FEMALE;Stage IV;Mixed serous and endometrioid;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;72;Metastatic;Lung;#N/A;60;Progressive Disease
TCGA-EO-A1Y7;UCEC;65;FEMALE;Stage IB;Endometrioid endometrial adenocarcinoma;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;WITH TUMOR;#N/A;Distant Metastasis;Lung;#N/A;880;Progressive Disease
TCGA-EO-A2CH;UCEC;73;FEMALE;Stage IVB;Serous endometrial adenocarcinoma;G3;2009;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;590;Metastatic;Liver;#N/A;304;Progressive Disease
TCGA-EY-A1GW;UCEC;73;FEMALE;Stage IVB;Endometrioid endometrial adenocarcinoma;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;337;Metastatic;Liver;#N/A;190;Progressive Disease
TCGA-EY-A2ON;UCEC;61;FEMALE;Stage IVB;Serous endometrial adenocarcinoma;G3;2011;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;610;#N/A;#N/A;#N/A;226;Progressive Disease
TCGA-EY-A4KR;UCEC;56;FEMALE;Stage IIIC1;Serous endometrial adenocarcinoma;G3;2012;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;346;#N/A;#N/A;#N/A;#N/A;Progressive Disease
TCGA-QS-A8F1;UCEC;85;FEMALE;Stage IIIA;Serous endometrial adenocarcinoma;G3;2013;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;135;#N/A;#N/A;#N/A;#N/A;Progressive Disease
TCGA-AJ-A23M;UCEC;61;FEMALE;Stage II;Serous endometrial adenocarcinoma;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;616;Locoregional Recurrence;Other, specify;Abdominal Fluid;516;Stable Disease
TCGA-BG-A0MQ;UCEC;71;FEMALE;Stage IA;Endometrioid endometrial adenocarcinoma;G1;2008;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;WITH TUMOR;#N/A;#N/A;#N/A;#N/A;#N/A;Stable Disease
TCGA-BS-A0TA;UCEC;58;FEMALE;Stage IVB;Endometrioid endometrial adenocarcinoma;G3;2005;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;740;#N/A;#N/A;#N/A;394;Stable Disease
TCGA-EY-A1GS;UCEC;71;FEMALE;Stage IVB;Serous endometrial adenocarcinoma;G3;2010;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Dead;WITH TUMOR;670;#N/A;#N/A;#N/A;#N/A;Stable Disease
TCGA-QS-A5YR;UCEC;61;FEMALE;Stage IIIB;Endometrioid endometrial adenocarcinoma;G2;2012;Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);Alive;WITH TUMOR;#N/A;#N/A;#N/A;#N/A;#N/A;Stable Disease